Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Science, Tohoku University, Miyagi, Japan.
Antimicrob Agents Chemother. 2013 Mar;57(3):1332-8. doi: 10.1128/AAC.01900-12. Epub 2012 Dec 28.
The antifungal efficacy of voriconazole (VRC) differs among host species, with potent efficacy in humans but less in rodents. We investigated the possible involvement of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) in the species-specific efficacy of VRC through pharmacokinetic analyses using genetically modified mice and primary human hepatocytes. VRC (30 mg/kg) was orally administered to wild-type, Pxr-null, Car-null, and Pxr- and Car-null (Pxr/Car-null) mice for 7 days. Hepatic VRC metabolism was significantly increased by VRC administration, and the elimination rates of plasma VRC were much higher on day 7 than on day 1 in wild-type mice. This autoinduction was also observed in Pxr-null and Car-null mice but not in Pxr/Car-null mice, suggesting coordinated roles of PXR and CAR in the autoinduction of VRC metabolism in mice. Hepatic Cyp3a11 mRNA levels were increased by VRC administration, hepatic metabolic activities for VRC were correlated with CYP3A activities, and the induced VRC metabolism was inhibited by ketoconazole (a CYP3A inhibitor). In primary human hepatocytes, VRC barely increased mRNA levels of CYP3A4 and CYP2B6 (human PXR/CAR target genes) at its therapeutic concentrations. In conclusion, these results suggest that VRC is metabolized mainly by CYP3A11 in mouse livers and that PXR- and CAR-mediated CYP3A11 induction, namely, autoinduction of VRC metabolism, is a primary reason for the ineffectiveness of VRC in mice. A limited ability of VRC to activate human PXR/CAR at its clinical concentration might explain the VRC efficacy in humans. Therefore, the ability to activate PXR/CAR might determine the VRC efficacy in different mammalian species.
伏立康唑(VRC)在不同宿主物种中的抗真菌疗效不同,在人类中疗效较强,但在啮齿动物中则较弱。我们通过使用基因修饰小鼠和原代人肝细胞进行药代动力学分析,研究了 PXR( pregnane X receptor )和 CAR( constitutive androstane receptor )在 VRC 物种特异性疗效中的可能作用。将 VRC(30mg/kg)连续 7 天经口给予野生型、Pxr 基因敲除型、Car 基因敲除型和 Pxr 和 Car 双基因敲除型(Pxr/Car 双基因敲除型)小鼠。VRC 给药后明显增加了肝内 VRC 的代谢,并且与第 1 天相比,野生型小鼠第 7 天的血浆 VRC 消除率要高得多。这种自身诱导作用也发生在 Pxr 基因敲除型和 Car 基因敲除型小鼠中,但在 Pxr/Car 双基因敲除型小鼠中没有观察到,这表明 PXR 和 CAR 在 VRC 代谢的自身诱导中在小鼠中起协同作用。VRC 给药后肝 Cyp3a11 mRNA 水平增加,肝 VRC 代谢活性与 CYP3A 活性相关,酮康唑(CYP3A 抑制剂)抑制诱导的 VRC 代谢。在原代人肝细胞中,VRC 在其治疗浓度下几乎不会增加 CYP3A4 和 CYP2B6(人 PXR/CAR 靶基因)的 mRNA 水平。总之,这些结果表明,VRC 主要在小鼠肝脏中被 CYP3A11 代谢,并且 PXR 和 CAR 介导的 CYP3A11 诱导,即 VRC 代谢的自身诱导,是 VRC 在小鼠中无效的主要原因。在其临床浓度下,VRC 激活人 PXR/CAR 的能力有限,这可能解释了 VRC 在人类中的疗效。因此,激活 PXR/CAR 的能力可能决定了 VRC 在不同哺乳动物物种中的疗效。